Zentalis Pharmaceuticals Management
Management criteria checks 1/4
Zentalis Pharmaceuticals' CEO is Kim Blackwell, appointed in May 2022, has a tenure of 1.92 years. total yearly compensation is $36.61M, comprised of 1.2% salary and 98.8% bonuses, including company stock and options. directly owns 0.071% of the company’s shares, worth $657.08K. The average tenure of the management team and the board of directors is 0.4 years and 3.2 years respectively.
Key information
Kim Blackwell
Chief executive officer
US$36.6m
Total compensation
| CEO salary percentage | 1.2% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.07% |
| Management average tenure | less than a year |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29
Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Zentalis initiates multiple early-stage clinical trials for cancer
Jan 06Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Nov 28
Zentalis: An Interesting Small Molecule Oncology Developer For Your Watchlist
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$292m |
| Sep 30 2023 | n/a | n/a | -US$286m |
| Jun 30 2023 | n/a | n/a | -US$285m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$37m | US$432k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$232m |
| Jun 30 2022 | n/a | n/a | -US$182m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$793k | n/a | -US$159m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$179m |
| Mar 31 2021 | n/a | n/a | -US$152m |
| Dec 31 2020 | US$1m | n/a | -US$118m |
Compensation vs Market: Kim's total compensation ($USD36.61M) is above average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Kim's compensation has increased whilst the company is unprofitable.
CEO
Kim Blackwell (53 yo)
1.9yrs
Tenure
US$36,614,376
Compensation
Dr. Kimberly Lynn Blackwell, M.D. also known as Kim, serves as Scientific Co-Founder at Cereius, Inc. She serves as an Independent Director at Century Therapeutics, Inc. since June 2021. Dr. Blackwell has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$36.61m | 0.071% $ 657.1k | |
| Co-Founder | 1.9yrs | US$10.63m | 0.34% $ 3.1m | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | US$6.48m | 0.0097% $ 89.5k | |
| VP of Finance & Interim Principal Accounting Officer | no data | no data | 0.050% $ 461.0k | |
| Chief Scientific Officer | less than a year | no data | 0.0035% $ 32.4k | |
| Chief Medical Officer & Director | less than a year | no data | no data | |
| Chief Strategy Officer | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Executive Vice President of Clinical Development | less than a year | no data | no data |
0.4yrs
Average Tenure
52yo
Average Age
Experienced Management: ZNTL's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$36.61m | 0.071% $ 657.1k | |
| Co-Founder | 9.3yrs | US$10.63m | 0.34% $ 3.1m | |
| Chief Medical Officer & Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.6yrs | US$1.11m | 0.010% $ 93.6k | |
| Independent Chairman of the Board | 4.3yrs | US$786.05k | 0.18% $ 1.6m | |
| Independent Director | 3.2yrs | US$666.43k | 0.031% $ 283.7k | |
| Independent Director | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data |
3.2yrs
Average Tenure
52.5yo
Average Age
Experienced Board: ZNTL's board of directors are considered experienced (3.2 years average tenure).